Adaptive Phage Therapeutics Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, to Chief Medical Officer
Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has promoted Robert Hopkins, M.D., to Chief Medical Officer.
- Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has promoted Robert Hopkins, M.D., to Chief Medical Officer.
- Dr. Robert Hopkins joined Adaptive Phage Therapeutics in 2019, after serving as Senior Medical Advisor in the Division of Clinical Services (DCS) for the Biomedical Advanced Research and Development Authority (BARDA) in Washington, D.C.
- Combating infectious diseases presents a critical need that affects a large portion of the population, said Dr. Robert Hopkins.
- Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.